BioAtla IPO Presentation Deck

BioAtla at a Glance The Company Proprietary CAB technology creates antibodies that conditionally and reversibly bind to tumors, but not normal cells, enabling increased antibody potency and reduced toxicity Strong intellectual property rights, with 257 patents issued, 8 allowed applications, and 214 pending applications ⠀ 54 employees and contractors, with 10 employees holding Ph.D. degrees, and 1 with an M.D. degree · Reputable investor base with $166 million raised to date, with $72.5 million in recent Series D financing Committed BeiGene collaboration with $25 million received to date, and eligible to receive up to $225.5 million in future milestone payments Headquartered in San Diego, California in a -43,000 square foot office and lab facility Investor Base BOXER CAPITAL CORMORANT ASSET MANAGEMENT FARALLON Janus Henderson INVESTORS bicatla HBM Healthcare Investments Pfizer Ventures pappas CAPITAL SOLEUS CAPITAL

View entire presentation